$Standard BioTools (LAB.US)$
Standard BioTools Achieves New Record of the Most Protein Measurements on the Most Sample Types with Expansion of the SomaScan® 11K Platform
SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB), today announced that the SomaScan® 11K Platform now includes protein measurements on a broader range of sample types, including cerebrospinal fluid (CSF), aqueous humor, tissue homogenates and cell lysates. The SomaScan® Platf...

$Standard BioTools (LAB.US)$ Standard BioTools Purchases the Carterra® Lsa-Xt System to Accelerate Data Delivery and Provide Greater Validation to Somascan Customers

$Standard BioTools (LAB.US)$ Revenue was $46 million, up 81% year-over-year, with impact of SomaScan
assay services, kits and related revenue in 2024; and
-- Ended the quarter with cash, cash equivalents, restricted cash and
short-term investments of $464 million, after accounting for $71 million
cash payments for merger-related expenses, settlement of year-end
operating accruals, debt retirement and completed stock buybacks.

$Standard BioTools (LAB.US)$ Standard BioTools Introduces New High-Throughput Multiplexed Whole Slide Imaging Modalities Set to Redefine the boundaries of Tissue Imaging
2 MINUTES AGO, 8:00 AM EDT
VIA GLOBENEWSWIRE

$Standard BioTools (LAB.US)$ Standard BioTools Announces Multi-Year Strategic Engagement With Bristol Myers Squibb For Use Of The SomaScan Platform For Translational Medicine Research Through 2026
Benzinga· 1 min ago

$Standard BioTools (LAB.US)$ Standard BioTools Expects Combined Company Revenue Of $200M-$205M, Est $120.2M